ArticleEuropean journal of pediatrics2026
Effectiveness of colchicine preparation switching in pediatric colchicine-resistant familial Mediterranean fever: a real-world study.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colchicine preparation switching is recommended before interleukin-1 (IL-1) inhibitor therapy in pediatric patients with colchicine-resistant familial Mediterranean fever (crFMF); however, real-world outcomes after switching are not well characterized. We aimed to evaluate the effectiveness of colchicine preparation switching and to compare clinical outcomes between patients managed with switching alone and those who subsequently required IL-1 inhibitor therapy. This retrospective inception cohort study included 103 pediatric crFMF patients carrying biallelic pathogenic MEFV exon 10 variants who underwent a switch from coated to compressed colchicine between August 2016 and May 2025. Clinical, laboratory, and genetic data were collected. Disease activity was assessed using the Pras score, the International Severity Scoring System for familial Mediterranean fever, and the Mor score. Patients were classified according to IL-1 inhibitor requirement; treatment escalation was the primary endpoint. Following colchicine preparation switching, attack frequency and disease activity scores decreased significantly (all p < 0.001). Sixty-three patients (61.2%) showed significant reductions in all major attack manifestations, whereas among 40 patients (38.8%) requiring IL-1 inhibitors, only fever decreased significantly (p = 0.012).
conclusionColchicine preparation switching significantly reduced attack frequency and disease activity in children with crFMF and may represent an effective intermediate therapeutic strategy before escalation to IL-1 inhibitor therapy. WHAT IS KNOWN: • Colchicine preparation switching is recommended before IL-1 inhibitor therapy in colchicine-resistant familial Mediterranean fever (crFMF), but evidence supporting this approach in children is limited. • Previous studies have reported improved disease control after switching colchicine preparations. WHAT IS NEW: • This study provides long-term pediatric data on the clinical course after colchicine preparation switching, including subsequent escalation to IL-1 inhibitor therapy. • Patients requiring subsequent IL-1 inhibitor therapy developed earlier subclinical inflammation and showed a less complete clinical response after switching.
Indexed as
Identifiers
42773272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.